| HOME >> BIOLOGY >> TECHNOLOGY |
Further detailed PROSTVAC(TM) data presented at the ECCO 15 - 34th ESMO Congress
Further data from the Phase II study with PROSTVAC(TM) were presented at the European CanCer Organisation (ECCO), ECCO 15 - 34th ESMO Congress in Berlin in September. The data indicate the potential for a broader therapeutic use of PROSTVAC(TM) in metastatic prostate cancer
Important events after the period
Delivery of IMVAMUNE(R) to Canada completed
As planned, Bavarian Nordic has delivered 20,000 doses of IMVAMUNE(R) to the Canadian government. A pre-New Drug Submission (NDS) meeting with Health Canada (National Regulatory Authority) was held in October 2009 to discuss the potential to file an NDS in 2010 for IMVAMUNE(R) as a safer smallpox vaccine under a Notice of Compliance with Conditions (NOC/C). Conclusions from the meeting have not yet been finalised.
Encouraging data for MVA-BN(R) HIV multiantigen warrant further studies
Bavarian Nordic has completed the analysis of the Phase I/II studies with MVA-BN(R) HIV multiantigen. The final safety and immunogenicity data demonstrate that the vaccine induces a broad T cell response in HIV infected subjects. The high number of responders to the vaccine is encouraging and warrant further studies. Thus, in line with its strategy, Bavarian Nordic is now looking for a partner in order to secure the continued development of MVA-BN(R) HIV multiantigen in a full Phase II.
Bavarian Nordic acquires remaining shares in its subsidiary BN ImmunoTherapeutics Inc. and subsequently own 100% of the subsidiary
Bavarian Nordic has entered into a conditiona
'/>"/>
| Copyright©2009 PR Newswire. All rights reserved |